News

Caretaker Partners with Red One Medical to Expand Advanced Monitoring to More Veterans and Hospital Departments

Caretaker Medical and Red One Medical have partnered to enable safer healthcare for U.S. veterans at VA hospitals.

Caretaker’s VitalStream® will offer VA medical centers the ability to continuously and non-invasively monitor blood pressure, cardiac output, stroke volume, fluid responsiveness and other advanced hemodynamic parameters throughout all hospital departments. This level of monitoring has been previously unavailable outside of the operating room and intensive care unit, and is usually reserved for higher-risk patients and procedures since it involves invasive lines or uncomfortable and restrictive devices. VitalStream can expand advanced monitoring capabilities to more patients and can lead to earlier detection of clinical decompensation, promote root-cause identification and enable personalized treatment – all which can lead to better patient outcomes.

Low blood pressure (hypotension) in the perioperative period is common. Forty-four percent of noncardiac surgery patients experience intraoperative hypotension (IOH) with a mean arterial pressure (MAP) under 65 mmHg for over 10 minutes.1 And 48% of noncardiac surgery patients with IOH and 22% of patients without IOH experience postoperative hypotension of a MAP <65 mmHg within 48 hours of surgery.2 This increases the risk of perioperative morbidity and mortality including acute kidney injury (AKI) and myocardial injury.2,3 Many times, intraoperative BP is only checked every 2-5 minutes intraoperatively and every 15 minutes to 1 hour postoperatively using an oscillometric blood pressure cuff. This can result in undetected BP drops that increase the risk of poor outcomes for military veterans.

“We are excited to bring the VitalStream technology to VA hospitals and enable safer care for our nation’s veterans,” stated Johnny Mann, a military veteran and VP of Sales and Marketing at Caretaker Medical. “This innovative monitoring solution will empower VA clinicians to detect potential complications earlier, intervene more effectively, and ultimately improve patient outcomes for our heroes.”

VitalStream is the only wireless, wearable ICU-grade monitor to be clinically validated and FDA-cleared. It uses a low-pressure finger sensor and patented Pulse Decomposition Analysis (PDA™) to measure advanced hemodynamic parameters. Its compact size, portability and wireless design allows for continuity of monitoring throughout all phases of care.

“The use of VitalStream can benefit veterans in the emergency room, OR, catheterization lab, ICU and the floor by offering more comprehensive monitoring capabilities and a continuity of monitor, described Tim Fazekas, a Marine Corps veteran with extensive experience in field and hospital critical care, and clinical affairs specialist for Red One Medical. “It’s really the best non-invasive monitor available that a patient can wear.”

VitalStream is now available on the VA Federal Supply Schedule (VA FSS), a streamlined procurement method for the U.S Department of Veterans Affairs. The VA FSS provides VA hospitals with the ability to purchase the devices they need unincumbered.

VitalStream was previously added to ECAT, the procurement method for the Department of Defense (DOD), and is available to military units for use in the field.

“This expanded partnership shows our dedication to ensuring veterans have access to quality healthcare with best-in-class medical devices,” stated Red One Medical CEO, Charles Pollak. “VitalStream is an innovative patient monitor that can help improve care for all veterans and military members.”

Learn more here.

Recent News

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like

03/17/2026

AgroSpheres and Wilbur-Ellis® Announce California Approval of FUN-THYME™

AgroSpheres and Wilbur-Ellis today announced that FUN-THYME, a broad-spectrum biofungicide co-developed by the two companies, has been approved for use in California. With demonstrated effectiveness on grapes, berries, apples, cherries, tomatoes and almonds, the new registration unlocks access for California growers. As the largest specialty crop producer in the United States, California is a defining

03/16/2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75